NTEC लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 05:30):

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel...

Stats
आज की मात्रा	988 303
औसत मात्रा	1.05M
बाजार मूल्य	0.00
EPS	$0 ( 2021-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.345 (3.58%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-23	Hayes William B	Sell	250	Stock Option (right to buy)
2021-07-23	Hayes William B	Sell	250	Stock Option (right to buy)
2021-07-23	Hayes William B	Sell	500	Stock Option (right to buy)
2021-07-23	Karah Hila	Sell	281	Stock Option (right to buy)
2021-07-23	Karah Hila	Sell	250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 59 transactions
Buy: 3 599 185 \| Sell: 7 817 315

मात्रा सहसंबंध

लंबा: 0.44 (neutral)

छोटा: 0.85 (strong)

Signal:(64.456) Same movement expected

Intec Pharma Ltd सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Intec Pharma Ltd सहसंबंध - मुद्रा/वस्त्र

0.42
( neutral )

0.46
( neutral )

-0.20
( neutral )

0.28
( neutral )

-0.56
( weak negative )

-0.32
( neutral )

Intec Pharma Ltd वित्तीय

Annual	2020
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-14.30

FY	2020
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-14.30

FY	2019
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-112.74

FY	2018
राजस्व:	$0.00
सकल लाभ:	$0.00 (0.00 %)
EPS:	$-111.67

Financial Reports:

No articles found.

Intec Pharma Ltd

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.